Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6467)
All Articles published online
|
Publishing Process of This Article
|
Mar 28, 2015 (publication date) through May 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: A meta-analysis. World J Gastroenterol 2015; 21(12): 3706-3710 [PMID: 25834339 DOI: 10.3748/wjg.v21.i12.3706] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i12/3706.htm |
| Number | Citing Articles |
| 1 |
Anastasia A. Sachkova, Daria V. Andreeva, Alexander S. Tikhomirov, Alexander M. Scherbakov, Diana I. Salnikova, Danila V. Sorokin, Fedor B. Bogdanov, Yulia D. Rysina, Andrey E. Shchekotikhin, Ekaterina S. Shchegravina, Alexey Yu. Fedorov. Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase. Pharmaceutics 2022; 14(12): 2829 doi: 10.3390/pharmaceutics14122829
|
| 2 |
Anna Li, Fei-Yu Niu, Jie-Fei Han, Na-Na Lou, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Zhi Xie, Jian Su, Ning Zhao, Ying Huang, Yi-Long Wu. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer. Lung Cancer 2015; 90(3): 375 doi: 10.1016/j.lungcan.2015.10.021
|
| 3 |
Ulrich H. Weidle, Fabian Birzele, Achim Krüger. Molecular targets and pathways involved in liver metastasis of colorectal cancer. Clinical & Experimental Metastasis 2015; 32(6): 623 doi: 10.1007/s10585-015-9732-3
|
| 4 |
Conor A. Bradley, Philip D. Dunne, Victoria Bingham, Stephen McQuaid, Hajrah Khawaja, Stephanie Craig, Jackie James, Wendy L. Moore, Darragh G. McArt, Mark Lawler, Sonali Dasgupta, Patrick G. Johnston, Sandra Van Schaeybroeck. Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget 2016; 7(48): 78932 doi: 10.18632/oncotarget.12933
|
| 5 |
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim, Jin Lee, Hyun Joo Jang. Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis. Oncotarget 2017; 8(42): 73098 doi: 10.18632/oncotarget.20392
|
| 6 |
Melanie Gündert, Dominic Edelmann, Axel Benner, Lina Jansen, Min Jia, Viola Walter, Phillip Knebel, Esther Herpel, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, Barbara Burwinkel. Genome-wide DNA methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol classifier). Gut 2019; 68(1): 101 doi: 10.1136/gutjnl-2017-314711
|
| 7 |
Victoria Bingham, Leanne McIlreavey, Christine Greene, Edwina O’Doherty, Rebecca Clarke, Stephanie Craig, Manuel Salto-Tellez, Stephen McQuaid, Claire Lewis, Jacqueline James. RNAscope in situ hybridization confirms mRNA integrity in formalin-fixed, paraffin-embedded cancer tissue samples. Oncotarget 2017; 8(55): 93392 doi: 10.18632/oncotarget.21851
|
| 8 |
Conor A. Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, Alberto Bardelli, Christian Rolfo, Josep Tabernero, Hajrah A. Khawaja, Mark Lawler, Patrick G. Johnston, Sandra Van Schaeybroeck. Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. Nature Reviews Clinical Oncology 2017; 14(9): 562 doi: 10.1038/nrclinonc.2017.40
|
| 9 |
Seyed Mostafa Parizadeh, Reza Jafarzadeh‐Esfehani, Danial Fazilat‐Panah, Seyed Mahdi Hassanian, Soodabeh Shahidsales, Majid Khazaei, Seyed Mohammad Reza Parizadeh, Majid Ghayour‐Mobarhan, Gordon A. Ferns, Amir Avan. The potential therapeutic and prognostic impacts of the c‐MET/HGF signaling pathway in colorectal cancer. IUBMB Life 2019; 71(7): 802 doi: 10.1002/iub.2063
|
| 10 |
Sander P.J. Joosten, Marcel Spaargaren, Hans Clevers, Steven T. Pals. Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2020; 1874(2): 188437 doi: 10.1016/j.bbcan.2020.188437
|
| 11 |
Jung Han Kim, Bum Jun Kim, Hyeong Su Kim. Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. Oncotarget 2017; 8(43): 75478 doi: 10.18632/oncotarget.20796
|
| 12 |
Elmira Safaie Qamsari, Sepideh Safaei Ghaderi, Bahareh Zarei, Ruhollah Dorostkar, Salman Bagheri, Farhad Jadidi-Niaragh, Mohammad Hossein Somi, Mehdi Yousefi. The c-Met receptor: Implication for targeted therapies in colorectal cancer. Tumor Biology 2017; 39(5): 101042831769911 doi: 10.1177/1010428317699118
|
| 13 |
Carlos Eduardo Bonilla, Paola Montenegro, Juan Manuel O’Connor, Ovidio Hernando-Requejo, Enrique Aranda, José Pinto Llerena, Alejandra Llontop, Jorge Gallardo Escobar, María del Consuelo Díaz Romero, Yicel Bautista Hernández, Begoña Graña Suárez, Emilio J. Batagelj, Ahmad Wali Mushtaq, Jesús García-Foncillas. Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer. Cancers 2023; 15(17): 4373 doi: 10.3390/cancers15174373
|
| 14 |
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim. MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review. Oncotarget 2017; 8(43): 75500 doi: 10.18632/oncotarget.20824
|
| 15 |
Kshipra S. Karnik, Ishudeep Singh Narula, Aniket P. Sarkate, Pravin S. Wakte. Auto QSAR‐ A Fast Approach for Creation and Application of QSAR Models through Automation. ChemistrySelect 2020; 5(19): 5756 doi: 10.1002/slct.202000744
|
| 16 |
Qiu-Xiao Yu, Ping-Ying Fu, Chi Zhang, Li Li, Wen-Ting Huang. Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer. World Journal of Gastrointestinal Surgery 2024; 16(5): 1395-1406 doi: 10.4240/wjgs.v16.i5.1395
|
| 17 |
Jianjiang Fu, Xiaorui Su, Zhihua Li, Ling Deng, Xiawei Liu, Xuancheng Feng, Juan Peng. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 2021; 40(28): 4625 doi: 10.1038/s41388-021-01863-w
|
| 18 |
Balakarthikeyan Janani, Mayakrishnan Vijayakumar, Kannappan Priya, Jin Hee Kim, Ayman Geddawy, Mohammad Shahid, Mahmoud H. El-Bidawy, Sameer Al-Ghamdi, Mohammed Alsaidan, Mohammad Hassan Abdelzaher, Abubucker Peer Mohideen, Thiyagarajan Ramesh. A network-based pharmacological investigation to identify the mechanistic regulatory pathway of andrographolide against colorectal cancer. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.967262
|
| 19 |
Bettina Bohusné Barta, Ágnes Simon, Lőrinc Nagy, Titanilla Dankó, Regina Eszter Raffay, Gábor Petővári, Viktória Zsiros, Anna Sebestyén, Ferenc Sipos, Györgyi Műzes, Vladimir Trajkovic. Survival of HT29 cancer cells is influenced by hepatocyte growth factor receptor inhibition through modulation of self-DNA-triggered TLR9-dependent autophagy response. PLOS ONE 2022; 17(5): e0268217 doi: 10.1371/journal.pone.0268217
|
| 20 |
Farshid Dayyani, Jasmine Balangue, Jennifer Valerin, Matthew J. Keating, Jason A. Zell, Thomas H. Taylor, May T. Cho. A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma. Clinical Colorectal Cancer 2024; 23(1): 67 doi: 10.1016/j.clcc.2023.11.001
|
| 21 |
Nele Van Der Steen, Ingrid Garajova, Christian Rolfo, Andrea Cavazzoni, Elisa Giovannetti. Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. 2019; : 25 doi: 10.1016/B978-0-12-813753-6.00002-0
|
| 22 |
Kai Dai, Yin Wu, Sha She, Qian Zhang. Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2021; 13(12): 2029-2037 doi: 10.4251/wjgo.v13.i12.2029
Abstract(293) |
Core Tip(348) |
Full Article(HTML)(2049)
|
Full Article (PDF)-662K(248)
|
Full Article (Word)-162K(118)
|
Audio-551K(3)
|
Peer-Review Report-307K(62)
|
Answering Reviewers-145K(53)
|
Times Cited (0)
|
Total Visits (4804)
|
Open
|
| 23 |
Michael A. Rogers, Verena Kalter, Gemma Marcias, Marc Zapatka, Sebastian Barbus, Peter Lichter. CITED4 gene silencing in colorectal cancer cells modulates adherens/tight junction gene expression and reduces cell proliferation. Journal of Cancer Research and Clinical Oncology 2016; 142(1): 225 doi: 10.1007/s00432-015-2011-5
|
| 24 |
Zhiwei Shao, Haoqi Pan, Sheng Tu, Jingying Zhang, Sheng Yan, Anwen Shao. HGF/c-Met Axis: The Advanced Development in Digestive System Cancer. Frontiers in Cell and Developmental Biology 2020; 8 doi: 10.3389/fcell.2020.00801
|
| 25 |
Qing-Wen Zhang, Zi-Dan Ye, Chang Shen, Hong-Xia Tie, Lei Wang, Lei Shi. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 2019; 34(1): 124 doi: 10.1080/14756366.2018.1533822
|
| 26 |
Wenjing Zhang, Xuelian Zhang, Peng Cheng, Kelin Yue, Ming Tang, Yan Li, Qiang Guo, Yu Zhang. HSF4 promotes tumor progression of colorectal cancer by transactivating c-MET. Molecular and Cellular Biochemistry 2023; 478(5): 1141 doi: 10.1007/s11010-022-04582-2
|
| 27 |
Fatemeh Moosavi, Elisa Giovannetti, Luciano Saso, Omidreza Firuzi. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Critical Reviews in Clinical Laboratory Sciences 2019; 56(8): 533 doi: 10.1080/10408363.2019.1653821
|
| 28 |
Yu Sunakawa, Yasutoshi Kuboki, Jun Watanabe, Tetsuji Terazawa, Hisato Kawakami, Mitsuru Yokota, Masato Nakamura, Masahito Kotaka, Naotoshi Sugimoto, Hitoshi Ojima, Eiji Oki, Takeshi Kajiwara, Yoshiyuki Yamamoto, Yasushi Tsuji, Tadamichi Denda, Takao Tamura, Soichiro Ishihara, Hiroya Taniguchi, Takako Eguchi Nakajima, Satoshi Morita, Kuniaki Shirao, Naruhito Takenaka, Daisuke Ozawa, Takayuki Yoshino. Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer. Targeted Oncology 2024; 19(1): 59 doi: 10.1007/s11523-023-01027-8
|
| 29 |
Wei Meng, Tao Chen. Association between the HGF/c‑MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (Review). Oncology Reports 2021; 46(3) doi: 10.3892/or.2021.8142
|
| 30 |
Gemma R. Armstrong, Mohammed Ibrahim Khot, Jim P. Tiernan, Nick P. West, Sarah L. Perry, Tom I. Maisey, Thomas A. Hughes, David G. Jayne. The utility of c‐Met as a diagnostic tissue biomarker in primary colorectal cancer. International Journal of Experimental Pathology 2021; 102(3): 172 doi: 10.1111/iep.12395
|
| 31 |
Xiaoli Wu, Chun-Wei Chen, Sangeeta Jaiswal, Tse-Shao Chang, Ruoliu Zhang, Michael K. Dame, Yuting Duan, Hui Jiang, Jason R. Spence, Sen-Yung Hsieh, Thomas D. Wang. Near-Infrared Imaging of Colonic Adenomas In Vivo Using Orthotopic Human Organoids for Early Cancer Detection. Cancers 2023; 15(19): 4795 doi: 10.3390/cancers15194795
|
| 32 |
Ling Lim, Chao-Chih Wu, Yun-Ting Hsu, Fang-Ju Sun, Chih-Long Chang. Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology 2019; 58(1): 105 doi: 10.1016/j.tjog.2018.11.020
|
| 33 |
Fuyan Hu, Qing Wang, Zhiyuan Yang, Zeng Zhang, Xiaoping Liu. Network-based identification of biomarkers for colon adenocarcinoma. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07157-w
|
| 34 |
Jung Han Kim, Bum Jun Kim, Hyeong Su Kim. Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review. Oncotarget 2017; 8(68): 113120 doi: 10.18632/oncotarget.21303
|
| 35 |
Kyle C. Cuneo, Ranjit K. Mehta, Himabindu Kurapati, Dafydd G. Thomas, Theodore S. Lawrence, Mukesh K. Nyati. Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib. Translational Oncology 2019; 12(2): 209 doi: 10.1016/j.tranon.2018.10.005
|
| 36 |
Pauline Roussille, Gaelle Tachon, Claire Villalva, Serge Milin, Eric Frouin, Julie Godet, Antoine Berger, Sheik Emambux, Christos Petropoulos, Michel Wager, Lucie Karayan-Tapon, David Tougeron. Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases. Cancers 2018; 10(12): 504 doi: 10.3390/cancers10120504
|
| 37 |
Lili Duan, Wanli Yang, Xiaoqian Wang, Wei Zhou, Yujie Zhang, Jinqiang Liu, Hongwei Zhang, Qingchuan Zhao, Liu Hong, Daiming Fan. Advances in prognostic markers for colorectal cancer. Expert Review of Molecular Diagnostics 2019; 19(4): 313 doi: 10.1080/14737159.2019.1592679
|
| 38 |
Patrícia Dias Carvalho, Flávia Martins, Susana Mendonça, Andreia Ribeiro, Ana Luísa Machado, Joana Carvalho, Maria José Oliveira, Sérgia Velho. Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast‐secreted factors through the HGF/C‐MET axis. International Journal of Cancer 2022; 151(10): 1810 doi: 10.1002/ijc.34225
|
| 39 |
Jin Hui Teh, Ala Amgheib, Ruisi Fu, Chris Barnes, Joel Abrahams, Ali Ashek, Ning Wang, Zixuan Yang, Muneera Mansoorudeen, Nicholas J. Long, Eric O. Aboagye. Evaluation of [18F]AlF-EMP-105 for Molecular Imaging of C-Met. Pharmaceutics 2023; 15(7): 1915 doi: 10.3390/pharmaceutics15071915
|
| 40 |
Vincenzo Sforza, Erika Martinelli, Fortunato Ciardiello, Valentina Gambardella, Stefania Napolitano, Giulia Martini, Carminia della Corte, Claudia Cardone, Marianna L Ferrara, Alfonso Reginelli, Giuseppina Liguori, Giulio Belli, Teresa Troiani. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology 2016; 22(28): 6345-6361 doi: 10.3748/wjg.v22.i28.6345
|
| 41 |
Helgi Birgisson, Kostas Tsimogiannis, Eva Freyhult, Masood Kamali-Moghaddam. Plasma Protein Profiling Reveal Osteoprotegerin as a Marker of Prognostic Impact for Colorectal Cancer. Translational Oncology 2018; 11(4): 1034 doi: 10.1016/j.tranon.2018.05.012
|
| 42 |
Yi-Long Wu, Ross Andrew Soo, Giuseppe Locatelli, Uz Stammberger, Giorgio Scagliotti, Keunchil Park. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. Cancer Treatment Reviews 2017; 61: 70 doi: 10.1016/j.ctrv.2017.10.003
|
| 43 |
Sarah Wedden, Keith Miller, Ian M. Frayling, Teresa Thomas, Alina Chefani, Karolina Miller, Angela Hamblin, Jenny C. Taylor, Corrado D’Arrigo. Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience. Applied Immunohistochemistry & Molecular Morphology 2019; 27(6): e54 doi: 10.1097/PAI.0000000000000631
|
| 44 |
Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab. Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. CPT: Pharmacometrics & Systems Pharmacology 2021; 10(5): 428 doi: 10.1002/psp4.12602
|
| 45 |
Mansoor Saleh, Philippe A. Cassier, Lauriane Eberst, Gurudatta Naik, Van K. Morris, Shubham Pant, Catherine Terret, Ling Gao, Amanda Long, Huzhang Mao, Samuel McNeely, Erin K. Wagner, Roberto M. Carlesi, Siqing Fu. Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings. The Oncologist 2020; 25(11): e1628 doi: 10.1634/theoncologist.2020-0520
|
| 46 |
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters, Omidreza Firuzi. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Critical Reviews in Oncology/Hematology 2021; 160: 103234 doi: 10.1016/j.critrevonc.2021.103234
|
| 47 |
Meng Zhang, Guichao Li, Xiangjie Sun, Shujuan Ni, Cong Tan, Midie Xu, Dan Huang, Fei Ren, Dawei Li, Ping Wei, Xiang Du. MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma. Human Pathology 2018; 77: 108 doi: 10.1016/j.humpath.2018.03.024
|
| 48 |
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer: Targets and Therapy 2021; : 35 doi: 10.2147/LCTT.S269307
|
| 49 |
Chung Hyo Kang, Yeongrin Kim, Da Yeon Lee, Sang Un Choi, Heung Kyoung Lee, Chi Hoon Park. c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer. Cancers 2021; 13(22): 5738 doi: 10.3390/cancers13225738
|
| 50 |
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim, Hyun Joo Jang, Jin Lee. Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review. Oncotarget 2017; 8(52): 90351 doi: 10.18632/oncotarget.20087
|
| 51 |
Henrik Failmezger, Harald Hessel, Ansh Kapil, Günter Schmidt, Nathalie Harder. Spatial heterogeneity of cancer associated protein expression in immunohistochemically stained images as an improved prognostic biomarker. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.964716
|
| 52 |
Jonas P. Koch, Daniel M. Aebersold, Yitzhak Zimmer, Michaela Medová. MET targeting: time for a rematch. Oncogene 2020; 39(14): 2845 doi: 10.1038/s41388-020-1193-8
|
| 53 |
Xue Zhang, Jing Zuo, Long Wang, Jing Han, Li Feng, Yudong Wang, Zhisong Fan. Identification of differentially expressed genes between mucinous adenocarcinoma and other adenocarcinoma of colorectal cancer using bioinformatics analysis. Journal of International Medical Research 2020; 48(8): 030006052094903 doi: 10.1177/0300060520949036
|
| 54 |
Bing Liu, Zheng‑Zhi Liu, Mei‑Ling Zhou, Jian‑Wei Lin, Xue‑Mei Chen, Zhu Li, Wen‑Bin Gao, Zhen‑Dong Yu, Tao Liu. Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Molecular Medicine Reports 2019; doi: 10.3892/mmr.2019.10529
|
| 55 |
Wafaa M. Rashed, Mohamed A. Kandeil, Mohamed O. Mahmoud, Doha Maher, Sameera Ezzat, Mohamed H. Abdel-Rahman. MET canonical transcript expression is a predictive biomarker for chemo-sensitivity to MET-inhibitors in hepatocellular carcinoma cell lines. Journal of Cancer Research and Clinical Oncology 2021; 147(1): 167 doi: 10.1007/s00432-020-03395-4
|
| 56 |
Aiwu Ruth He, Roger B. Cohen, Crystal S. Denlinger, Ashwin Sama, Ariel Birnbaum, Jimmy Hwang, Takami Sato, Nancy Lewis, Michelle Mynderse, Michele Niland, Jennifer Giles, Johan Wallin, Brian Moser, Wei Zhang, Richard Walgren, Elizabeth R. Plimack. First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. The Oncologist 2019; 24(9): e930 doi: 10.1634/theoncologist.2018-0411
|